Skip to main content
    T

    Telix Pharmaceuticals Limited (TLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.92
    -0.31 (-3.36%)

    Market Cap: $3.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Telix Pharmaceuticals Limited (TLX) Financials: Revenue, Profit and Cash Flow

    Updated Aug 19, 2026. Financial statements from company filings, amounts in AUD.

    Telix Pharmaceuticals reported revenue of AUD 789.77M for the fiscal year ended Dec 31, 2025, up 0.8% from the year before. That year, operating cash flow was AUD -16.99M and free cash flow was AUD -54.25M. The quarter ended Jun 30, 2026 had revenue of AUD 476.04M and net income of AUD 38.22M.

    Revenue and Margins

    The operating margin was 2.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from AUD 29.40M, a compound annual rate of 44.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025789.77M+0.8%53.1%2.2%N/A
    Dec 2024783.21M+55.8%65.1%10.5%6.4%
    Dec 2023502.55M+213.9%62.6%3.2%1.0%
    Dec 2022160.10M+2007.6%59.3%-57.4%-65.0%
    Dec 20217.60M+45.7%66.5%-1069.6%-1059.9%
    Dec 20205.21M+49.6%61.2%-847.7%-861.1%
    Dec 20193.48M+1685.9%-340.7%-1033.6%-799.6%
    Dec 2018195.14K-99.4%100.0%-15016.1%-7087.1%
    Dec 201731.77M+8.0%0.0%-20.5%-20.1%
    Dec 201629.40MN/AN/A-0.1%-0.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue789.77M783.21M502.55M160.10M7.60M5.21M3.48M195.14K31.77M29.40M
    Cost of revenue370.31M273.53M188.16M65.17M38.68M2.02M15.36M16.08M3.79K21.35M
    Gross profit419.47M509.68M314.39M94.93M5.05M3.19M-11.88M195.14K-3.79KN/A
    Research and development168.26M121.03M128.84M57.86M34.13M23.09M21.16M18.69M2.98M10.00K
    Operating income17.46M82.13M15.84M-91.93M-81.25M-44.19M-36.02M-29.30M-6.52M-30.00K
    Net incomeN/A49.92M5.21M-104.08M-80.51M-44.89M-27.87M-13.83M-6.38M-44.00K
    EBITDA52.30M100.57M22.97MN/A-70.07MN/A-24.48M-29.30M-5.68M-14.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021Jun 2021Dec 2020
    Revenue476.04M410.04M355.14M594.24M188.96M281.71M220.83M136.05M24.05M4.69M2.91M3.61M
    Gross profit245.55M216.39M172.65M385.80M123.88M223.97M90.81M44.89M-15.57M-18.86M-11.18M-8.25M
    Operating income-13.71M6.49M9.45M68.38M13.75M-15.60M31.44M-9.70M-63.49M-49.92M-31.60M-29.14M
    Net income38.22M-4.79M-2.09M38.24M11.68M19.53M-14.32M-33.19M-70.89M-48.00M-32.51M-26.59M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of AUD 410.57M exceeded cash and equivalents by 268.75M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets1.18B1.52B398.30M255.35M109.81M157.82M102.61M76.71M51.09M18.61M
    Current assets330.18M918.56M224.85M173.23M47.54M93.63M58.68M35.86M49.55MN/A
    Cash and equivalents141.82M710.35M123.24M116.33M22.04M77.94M44.60M25.77M48.76MN/A
    Total liabilities766.49M948.22M249.39M175.35M106.17M78.81M32.53M23.80M1.80M20.38M
    Short-term debt18.65M21.49M1.56M1.28M632.00K767.00K490.00K1.13M345.43KN/A
    Long-term debt391.91M551.82M8.21M3.31MN/A95.00KN/AN/AN/AN/A
    Shareholder equity415.24M568.21M148.91M80.01M2.16M79.02M70.08M52.90M49.29M-1.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021Jun 2021Dec 2020
    Total assets1.36B1.18B1.20B1.52B745.96M398.30M310.34M255.35M215.94M109.81M128.84M157.82M
    Total liabilities873.85M766.49M772.03M948.22M341.98M249.39M234.28M175.35M110.53M107.66M80.91M78.81M
    Cash and equivalents251.82M141.82M208.24M710.35M118.84M123.24M131.73M116.33M122.61M22.04M49.62M77.94M
    Shareholder equity487.49M415.24M421.94M568.21M403.97M148.91M76.06M80.01M105.41M2.16M47.93M79.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-16.99M43.03M23.88M-63.97M-59.33M1.96M-23.33M-20.75M-6.03MN/A
    Capital expenditures37.25M14.32M9.68M7.04M1.34M248.00K403.00K198.73K5.64KN/A
    Free cash flow-54.25M28.71M14.21M-71.01M-60.67M1.71M-23.74M-20.95M-6.04MN/A
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/A54.79MN/A
    Investing cash flow-280.93M-135.17M-25.49M-17.00M-2.73M-1.09M-468.00K-2.69M-1.26KN/A
    Financing cash flow-3.65M638.92M10.19M174.96M2.85M34.12M42.72M-869.00K54.79MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
    Operating cash flow22.97M-34.73M16.15M3.95M34.98M10.63M13.26M-3.75M
    Capital expenditures18.91M26.47M6.07M9.63M4.60M6.67M3.01M4.66M
    Free cash flow4.06M-61.20M10.08M-5.68M30.38M3.96M10.25M-8.41M
    Last 8 quarters

    Frequently Asked Questions About TLX

    What is Telix Pharmaceuticals' annual revenue?

    Telix Pharmaceuticals reported revenue of AUD 789.77M for the fiscal year ended Dec 31, 2025.

    How fast is Telix Pharmaceuticals' revenue growing?

    Revenue was up 0.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 70.2%.

    How much free cash flow does TLX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of AUD -16.99M minus capital expenditures of AUD 37.25M produced free cash flow of AUD -54.25M.

    How much debt does Telix Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of AUD 391.91M, short-term debt of AUD 18.65M and cash and equivalents of AUD 141.82M.

    What is TLX's profit margin?

    For the fiscal year ended Dec 31, 2025, Telix Pharmaceuticals reported gross margin of 53.1% and operating margin of 2.2%.